Viewpoint Molecular Targeting

Viewpoint Molecular Targeting is a radiopharmaceutical company that develops precision oncology therapeutics and complementary diagnostic imaging agents. The company's proprietary technology utilizes the isotope lead-212 to deliver powerful alpha radiation specifically to cancer cells via specialized targeting peptides. Viewpoint is employing a "theranostic" approach, developing imaging diagnostics that incorporate the same targeting peptides to visualize tumors and personalize treatment, potentially improving efficacy and minimizing toxicity associated with other cancer treatments.

Viewpoint's lead programs are VMT01 for metastatic melanoma and VMT-α-NET for neuroendocrine tumors. In September 2021, the US Food and Drug Administration cleared an Investigational New Drug application for a Phase 1 imaging study of VMT-α-NET, which will evaluate it as an agent for imaging somatostatin receptor subtype 2-positive neuroendocrine tumors. The images obtained will inform future therapeutic trials of VMT-α-NET alpha-particle therapy for this tumor type. In January 2023, Viewpoint announced the first dosing of two neuroendocrine tumor patients with therapeutic intent under compassionate use circumstances.

Viewpoint has also developed a proprietary lead-212 generator to secure isotope supply for clinical trials and commercial operations. In September 2022, Viewpoint entered into a definitive agreement to merge with Isoray, Inc., a medical technology company and innovator in seed brachytherapy, with the merger closing in February 2023.